科倫藥業:湖南科倫注射用奧美拉唑鈉通過仿制藥一致性評價 將進一步提升産品市場競爭力 2021-05-21T06:05:34-04:00May 21st, 2021| share this article!科倫藥業子公司湖南科倫制藥有限公司于近日獲得國家藥品監督管理局核准簽發的化學藥品「注射用奧美拉唑鈉」的《藥品補充申請批准通知書》。本次公司注射用奧美拉唑鈉通過一致性評價,將進一步提升該産品的市場競爭力。 Read More share this article! Related Posts Vietnam’s Galaxy Education eyes up to $20m fundraising to expand footprint May 3rd, 2024 Sony looks to boost film assets with $26bn Paramount acquisition May 3rd, 2024 Soundwill pushes to revalue Causeway Bay site as demand declines May 3rd, 2024 Hang Seng Bank maintains HKD lending and savings rate May 3rd, 2024